List of Excipients in Branded Drug HEPAGAM B

HEPAGAM B Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 26, 2026

HEPAGAM B is a plasma-derived hepatitis B immune globulin product whose commercial differentiation depends more on supply reliability, administration convenience, viral-safety controls, and channel access than on a complex excipient platform. Its labeled formulation uses glycine and polysorbate 80 in water for injection. The main excipient opportunities are stability improvement, low-particle presentation, ready-to-administer packaging, and compatibility with intramuscular and intravenous use. Any reformulation would require a biologics comparability package and could create new formulation or container-closure patent opportunities, but it would also introduce regulatory and manufacturing risk.

What is HEPAGAM B and how is it formulated?

HEPAGAM B is hepatitis B immune globulin intravenous or intramuscular, manufactured from human plasma containing high titers of antibodies to hepatitis B surface antigen. The product is indicated for postexposure prophylaxis and prevention of hepatitis B recurrence in liver-transplant recipients. It is administered intramuscularly or intravenously depending on the clinical use and dose. [1]

HEPAGAM B labeled composition

Attribute	HEPAGAM B
Active ingredient	Hepatitis B immune globulin, human
Antibody target	Hepatitis B surface antigen
Strength	156 IU/mL
Dosage forms	Intramuscular and intravenous use
Labeled excipients	Glycine, polysorbate 80, water for injection
Product type	Plasma-derived biologic
U.S. approval pathway	Biologics license application
U.S. approval date	2006
Principal formulation role	Protein stabilization, solubilization, and injectable presentation

The formulation is deliberately simple. Glycine acts primarily as a stabilizing amino acid and contributes to osmolality. Polysorbate 80 is a nonionic surfactant used to reduce protein adsorption at air-liquid and liquid-container interfaces. Water for injection is the vehicle. [1]

The limited excipient system reduces labeling complexity and simplifies manufacturing, but it concentrates technical risk in the protein, surfactant, container closure, and cold-chain system.

What excipients protect HEPAGAM B stability?

The key formulation risks are immunoglobulin aggregation, subvisible particles, surface adsorption, polysorbate degradation, and loss of antibody activity during storage or administration.

Glycine

Glycine is commonly used in immunoglobulin products as a stabilizer. It can reduce protein unfolding and help maintain a suitable osmolality range. Its advantages include broad regulatory familiarity, low molecular weight, and compatibility with parenteral products.

Commercial limitations include:

• Limited ability to control all aggregation pathways by itself.
• Potential need for pH optimization around the immunoglobulin stability profile.
• Restricted flexibility if the product must support both intramuscular and intravenous administration.
• Limited differentiation because glycine is a conventional excipient used in multiple plasma-derived products.

A reformulation using alternative amino acids, sugars, polyols, or combinations would need to demonstrate equivalent potency, purity, aggregate control, particle profile, sterility, and tolerability.

Polysorbate 80

Polysorbate 80 protects immunoglobulin against interfacial stress during filling, transport, handling, and administration. It is particularly relevant for products exposed to agitation, pumps, syringes, and tubing.

The main technical concern is degradation. Polysorbate 80 can undergo hydrolysis and oxidation, producing free fatty acids and peroxide species. Those degradation products can promote protein oxidation, visible particles, or subvisible particle formation. The risk is affected by raw-material quality, oxygen exposure, light, trace metals, storage temperature, and container closure. [2,3]

A commercial excipient strategy should therefore include:

1. Tight control of polysorbate identity and quality attributes.
2. Monitoring of degradation products over the full shelf life.
3. Control of oxygen ingress and headspace conditions.
4. Compatibility testing with vials, stoppers, syringes, needles, and infusion systems.
5. Particle testing after shipping simulation and repeated handling.

Replacing polysorbate 80 with polysorbate 20 or another surfactant could create a differentiated formulation, but it would not automatically improve the product. The replacement must show lower degradation, equal or better immunoglobulin stability, and no new safety or administration problems.

What formulation patents could protect a HEPAGAM B successor?

A new formulation could be patentable if it provides a non-obvious technical result, such as materially improved stability, reduced particles, lower surfactant degradation, or a new administration format. The strongest potential claims would likely cover a defined combination of:

• Hepatitis B immune globulin concentration.
• pH range.
• Glycine or alternative stabilizer concentration.
• Surfactant identity and concentration.
• Antioxidant or chelator system.
• Residual moisture or oxygen limits.
• Container-closure configuration.
• Storage temperature and shelf life.
• Administration through a prefilled syringe or infusion device.

Potential formulation claim areas

Strategy	Possible commercial benefit	Main development barrier
Optimized glycine-polysorbate system	Longer shelf life and fewer particles	Must prove meaningful improvement over the reference formulation
Alternative surfactant	Lower oxidation or hydrolysis risk	New extractables, tolerability, and comparability work
Low-surfactant formulation	Cleaner degradation profile	Greater risk of adsorption and aggregation
Sugar or polyol stabilizer	Improved freeze-thaw or thermal stability	Osmolality and injection tolerability
Antioxidant or chelator	Lower oxidation	New impurity and safety assessment
Ready-to-use prefilled syringe	Reduced preparation time and dosing errors	Device compatibility, extractables, and particulate control
High-concentration formulation	Lower injection volume	Viscosity, pain, aggregation, and delivery constraints
Room-temperature-stable product	Lower distribution cost	Difficult stability target for a plasma-derived protein

Patent protection would be stronger when tied to measured performance rather than a broad list of conventional excipients. A claim covering “an immunoglobulin and a stabilizer” would face substantial prior-art risk. Claims tied to a narrow composition and demonstrated stability profile would be more defensible.

When does HEPAGAM B lose exclusivity?

HEPAGAM B received FDA approval in 2006. The 12-year reference-product exclusivity period for a licensed biologic would generally have ended in 2018, subject to the specific statutory calculation and any applicable pediatric exclusivity. Biologic exclusivity does not block all competition after that date; it primarily governs when a biosimilar application may be submitted and approved. [4]

Exclusivity issue	HEPAGAM B position
FDA approval	2006
Reference biologic exclusivity	Statutory period generally expired by 2018
Small-molecule generic pathway	Not applicable
ANDA substitution	Not applicable
Biosimilar pathway	Available in principle
Interchangeability	Requires a separate FDA determination
Orange Book listing	Not the principal U.S. patent mechanism for this biologic

A biologic can continue to face patent barriers after statutory exclusivity expires. Those barriers may include manufacturing methods, purification processes, formulations, delivery devices, and use patents. The existence and enforceability of those rights must be assessed through a current patent and litigation search.

What is the Orange Book status of HEPAGAM B?

HEPAGAM B is regulated as a biologic, not as a conventional small-molecule drug. The FDA Orange Book is therefore not the primary source for its exclusivity or patent status. Biologic reference products and biosimilars are tracked through the FDA Purple Book. [5]

A competitor would generally pursue one of two routes:

• A biosimilar application under the Public Health Service Act.
• A separate biologic or licensed plasma-derived product supported by its own manufacturing and clinical package.

A Paragraph IV certification is associated with the abbreviated new drug application pathway for small-molecule products. It is not the ordinary mechanism for challenging a stand-alone biologic such as HEPAGAM B.

Are there biosimilar or generic risks for HEPAGAM B?

The practical competitive risk is more likely to come from another hepatitis B immune globulin product than from an interchangeable biosimilar.

Why biosimilar competition is difficult

Hepatitis B immune globulin is a heterogeneous plasma-derived product. Its composition depends on donor-pool selection, antibody titers, fractionation, purification, viral inactivation, nanofiltration, formulation, and release testing. These variables complicate the development of a highly similar product.

A competitor must address:

• Source plasma qualification.
• High-titer donor recruitment.
• Viral clearance and pathogen safety.
• Immunoglobulin purity and aggregate control.
• Anti-HBs potency.
• Lot-to-lot consistency.
• Clinical pharmacology and immunogenicity.
• Supply continuity during demand spikes.

The regulatory burden creates a meaningful manufacturing barrier even where formal reference-product exclusivity has expired. FDA biosimilar policy allows different excipients from the reference product in some circumstances, but the proposed product must remain highly similar and clinically non-inferior in relevant respects. [6]

Competitive products

The U.S. hepatitis B immune globulin market includes HEPAGAM B and other products such as Nabi-HB and HyperHEP S/D. Product positioning can vary by route, dosage presentation, indication, hospital contracting, and supply availability. [7,8]

Competitive factor	HEPAGAM B opportunity
Liver-transplant prophylaxis	Specialist hospital and transplant-center contracting
Occupational exposure	Emergency department and occupational-health access
Neonatal or perinatal prophylaxis	Institutional protocols and public-health purchasing
Intravenous use	Differentiation through infusion convenience and stability
Intramuscular use	Low-volume, ready-to-administer presentation
Supply continuity	Contracting advantage where plasma supply is constrained
Excipient simplicity	Lower formulation complexity and familiar ingredients

What commercial opportunities exist for an improved HEPAGAM B formulation?

The highest-value opportunities are operational rather than purely chemical.

Ready-to-administer delivery

A prefilled syringe or integrated administration system could reduce preparation steps, dosing errors, and product waste. The formulation must remain stable in the device, including under shipping vibration, temperature excursions, and extended contact with elastomers or lubricants.

A device-based product could support premium pricing if it reduces total administration cost. The economic case would be strongest in emergency departments, transplant centers, occupational-health clinics, and neonatal units.

Lower-volume dosing

A higher-concentration formulation could reduce injection volume. This may improve intramuscular administration, but viscosity and injection force increase as protein concentration rises. Higher concentration can also increase aggregation risk and may require a different surfactant or container system.

The commercial value depends on whether lower volume improves patient acceptance, administration time, or use in small infants. It would not be sufficient to show only chemical stability; injection tolerability and device performance would also matter.

Improved thermal stability

A product that tolerates short excursions above refrigerated conditions could reduce wastage and expand distribution into lower-resource settings. This opportunity has a large technical barrier because immunoglobulin stability is sensitive to temperature, agitation, and interfaces.

The strongest product claim would combine:

• A specified formulation.
• A defined temperature-excursion profile.
• Retained anti-HBs potency.
• Controlled aggregates and particles.
• A validated container-closure system.

Lower particle burden

Hospitals increasingly prioritize injectable products with predictable particulate profiles. A formulation and container system that reduces visible and subvisible particles could improve procurement positioning, especially for intravenous use.

The development program should evaluate particles after:

• Long-term storage.
• Accelerated stability.
• Freeze-thaw exposure.
• Shipping simulation.
• In-use dilution.
• Contact with infusion bags and tubing.
• Repeated syringe transfers.

Global access and supply partnerships

HBIG demand is tied to transplant activity, perinatal prevention, occupational exposure, and public-health programs. A company with reliable plasma sourcing and regional fill-finish capacity could compete through supply assurance rather than formulation novelty.

Licensing opportunities may include:

• Regional commercialization rights.
• Plasma-supply agreements.
• Fill-finish partnerships.
• Hospital group purchasing contracts.
• Co-development of a prefilled presentation.
• Public-sector procurement programs.

No specific HEPAGAM B licensing transaction or settlement agreement is identified here as a basis for valuation. Transaction diligence should rely on current SEC filings, FDA records, court dockets, and license agreements.

How strong is the HEPAGAM B patent estate?

The likely defensibility of the product does not rest on excipient novelty alone. Glycine and polysorbate 80 are established pharmaceutical excipients, so broad composition claims would face prior-art pressure. Stronger protection would come from a narrow, enabled combination that solves a documented stability or delivery problem.

Patent-strength factors

Factor	Assessment
Conventional excipients	Weak basis for broad exclusivity
Defined concentration and pH	Moderate potential if tied to unexpected performance
Surfactant-degradation control	Potentially strong if supported by comparative data
Container-closure claims	Useful for lifecycle protection
Prefilled-device claims	Commercially relevant, but vulnerable to design-around
Manufacturing and purification	Potentially important because plasma products are difficult to reproduce
Method-of-use claims	Relevant to transplant and prophylaxis markets, but indication scope matters
Biosimilar barrier	Manufacturing similarity and supply chain may be more important than formulation patents

Method-of-use protection could target specific dosing schedules, transplant timing, or combination use with vaccination. Such claims must be assessed against clinical practice, labeling, written description, enablement, and prior-art limitations.

What litigation and generic launch risks affect HEPAGAM B?

A generic launch scenario is not the appropriate baseline because HEPAGAM B is a biologic. The realistic scenarios are:

1. A competing licensed HBIG product enters through an independent biologic strategy.
2. A biosimilar or highly similar product is developed after analytical and clinical comparability work.
3. A competitor designs around formulation or device claims.
4. A supplier or contract manufacturer becomes a source of manufacturing-related competition.
5. A plasma shortage creates temporary commercial advantage for products with diversified sourcing.

Potential litigation would likely concern formulation patents, purification methods, viral-inactivation processes, device patents, trade secrets, or contract rights. A current docket review is required before assigning a litigation probability or launch date.

Key Takeaways

• HEPAGAM B uses a simple labeled excipient system of glycine, polysorbate 80, and water for injection.
• The main formulation risks are immunoglobulin aggregation, particles, surfactant degradation, and container interaction.
• The strongest lifecycle opportunity is a ready-to-administer, low-volume, particle-controlled presentation.
• A Paragraph IV challenge is not the normal route for HEPAGAM B because it is a biologic.
• Reference-product exclusivity from the 2006 approval has generally expired, but manufacturing and formulation barriers remain relevant.
• Biosimilar competition is technically difficult because HBIG is a heterogeneous, plasma-derived product.
• Broad claims to conventional excipients would likely be weak; narrow claims tied to demonstrated stability or device performance would be more valuable.
• Commercial value is concentrated in transplant centers, emergency departments, occupational-health providers, neonatal prophylaxis, and public-health procurement.

FAQs

Can polysorbate 80 be removed from HEPAGAM B?

It could be evaluated, but removal would increase the risk of protein adsorption and aggregation. A surfactant-free formulation would require comparative stability, particle, potency, container-compatibility, and administration studies.

Could HEPAGAM B be converted into a subcutaneous product?

Subcutaneous delivery would require a different concentration, volume, injection-device, and tolerability strategy. The high protein dose required for some HBIG uses may make subcutaneous delivery commercially difficult without a concentrated formulation or alternate dosing schedule.

What is the most valuable HEPAGAM B formulation patent?

A patent covering a defined formulation that materially reduces polysorbate degradation and immunoglobulin particles over an extended shelf life would likely have greater commercial value than a broad claim covering glycine and a surfactant.

Can a hospital substitute another HBIG product automatically?

Automatic substitution depends on the product’s FDA status, labeling, institutional policy, payer rules, and whether the products are considered interchangeable for the intended use. Biologic substitution does not operate under the same framework as ordinary generic substitution.

Does HEPAGAM B require cold-chain distribution?

The labeled storage requirements should control commercial handling. Any proposal for room-temperature distribution would require product-specific stability data and FDA-approved labeling supporting the new storage condition.

References

1. U.S. Food and Drug Administration. (2023). HEPAGAM B: Hepatitis B immune globulin intravenous or intramuscular prescribing information. FDA.

2. U.S. Food and Drug Administration. (2016). Review and evaluation of pharmacology and toxicology data for polysorbate excipients and related formulation considerations. FDA.

3. European Medicines Agency. (2017). Questions and answers on the assessment of extractables and leachables in medicinal products. EMA.

4. U.S. Code. (2024). 42 U.S.C. § 262: Regulation of biological products.

5. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. FDA.

6. U.S. Food and Drug Administration. (2015). Scientific considerations in demonstrating biosimilarity to a reference product: Guidance for industry. FDA.

7. U.S. Food and Drug Administration. (2023). Nabi-HB hepatitis B immune globulin human prescribing information. FDA.

8. U.S. Food and Drug Administration. (2023). HyperHEP S/D hepatitis B immune globulin human prescribing information. FDA.